Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a US-listed Healthcare company in Biotechnology with a market capitalization of $98M, trading at $48.90 on the NASDAQ. This SniperIQ fundamentals page covers Hemab Therapeutics Holdings, Inc. Common Stock's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hemab Therapeutics Holdings, Inc. Common Stock's market cap?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has a market capitalization of approximately $98M, trading at $48.90 on the NASDAQ. Market cap moves with the live share price.
How profitable is Hemab Therapeutics Holdings, Inc. Common Stock?
Hemab Therapeutics Holdings, Inc. Common Stock runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Hemab Therapeutics Holdings, Inc. Common Stock pay a dividend?
Hemab Therapeutics Holdings, Inc. Common Stock does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hemab Therapeutics Holdings, Inc. Common Stock financially healthy?
Hemab Therapeutics Holdings, Inc. Common Stock carries a debt-to-equity ratio of -0.01x and a current ratio of 18.03x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hemab Therapeutics Holdings, Inc. Common Stock a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hemab Therapeutics Holdings, Inc. Common Stock (COAG) the key facts are: market cap $98M, 52-week range 23-52.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hemab Therapeutics Holdings, Inc. Common Stock's full fundamentals live
Get Hemab Therapeutics Holdings, Inc. Common Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.